Related Experiment Videos

Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1

J W B Bainbridge1, A Mistry, M De Alwis

  • 1Department of Molecular Genetics, Institute of Ophthalmology, University College London, London, UK.

Gene Therapy
|April 9, 2002
PubMed

Insights

Gene transfer of soluble VEGF receptor sFlt-1 effectively inhibited retinal neovascularization by approximately 50% in a mouse model. This approach offers a promising new strategy for treating blinding neovascular eye diseases.

Area of Science:

  • Ophthalmology
  • Gene Therapy
  • Vascular Biology

Background:

  • Retinal angiogenesis contributes to major causes of blindness.
  • Current treatments for these conditions have limited efficacy and adverse effects.

Purpose of the Study:

  • To evaluate the angiostatic effect of gene transfer of soluble VEGF receptor sFlt-1.
  • To assess the efficacy of adenovirus and adeno-associated virus (AAV) vectors for delivering sFlt-1 in a mouse model of retinal neovascularization.

Main Methods:

  • Proliferative retinopathy was induced in mice via oxygen exposure.
  • Intravitreal injection of recombinant viral vectors expressing green fluorescent protein (GFP) or sFlt-1 was performed.
  • sFlt-1 expression was confirmed by ELISA; neovascularization was quantified.

Main Results:

  • Adenovirus and AAV vectors mediated efficient gene expression in specific retinal cells.
  • Vector-mediated sFlt-1 expression significantly reduced neovascular endothelial cells by 56% (adenovirus) and 52% (AAV).
  • Both vectors demonstrated a statistically significant reduction (P < 0.05) in experimental retinal neovascularization.

Conclusions:

  • Local gene transfer of sFlt-1 effectively inhibits experimental retinal neovascularization by approximately 50%.
  • This gene therapy approach represents a novel and powerful strategy for managing retinal neovascular disorders.

Related Concept Videos